Public Policy and Big Pharma M&A: Prices, Patents and Taxes
This article was originally published in RPM Report
Executive Summary
Big Pharma M&A is back in the headlines, though so far the biggest deals have been talked about but not completed. While the business elements of each of the deals are different, there are some common public policy themes.
You may also be interested in...
Teva’s Generic Viagra Launch Will Be Offset By Generic Cialis
Patent settlement will enable Teva to enter the market more than three years before Viagra’s use patent expires; Pfizer suddenly parts ways with General Counsel Amy Schulman.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.